These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 11970762

  • 1. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD, Ogden JL, Jain VK.
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F, Mounier N, Sebban C, Brice P, Solal-Celigny P, Tilly H, Feugier P, Fermé C, Copin MC, Lamy T.
    Cancer; 2010 Sep 15; 116(18):4299-308. PubMed ID: 20549824
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N, LaRocca RV, Bard V, Sethuraman G, Foon KA.
    Am J Hematol; 2002 Jul 15; 70(3):181-5. PubMed ID: 12111762
    [Abstract] [Full Text] [Related]

  • 4. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M.
    Lancet Oncol; 2008 Apr 15; 9(4):352-8. PubMed ID: 18342572
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, Chou T, Aikawa K, Uike N, Mizorogi F, Ohno T, Ikeda S, Sai T, Taniwaki M, Kawano F, Niimi M, Hotta T, Shimoyama M, Tobinai K, Members of the lymphoma study group of the Japan Clinical Oncology Group (JCOG).
    Ann Oncol; 2002 Sep 15; 13(9):1347-55. PubMed ID: 12196359
    [Abstract] [Full Text] [Related]

  • 6. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B.
    J Clin Oncol; 1995 Oct 15; 13(10):2530-9. PubMed ID: 7595704
    [Abstract] [Full Text] [Related]

  • 7. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
    Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ.
    J Clin Oncol; 2004 Dec 01; 22(23):4711-6. PubMed ID: 15483015
    [Abstract] [Full Text] [Related]

  • 8. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ, Yang JM, Song XM, Chen L, Zhang WP, Ni X, Xu XQ, Wang JM.
    Zhonghua Zhong Liu Za Zhi; 2007 Sep 01; 29(9):710-2. PubMed ID: 18246806
    [Abstract] [Full Text] [Related]

  • 9. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M.
    J Clin Oncol; 2013 Apr 20; 31(12):1506-13. PubMed ID: 23530110
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma.
    Cartron G, Voillat L, Desablens B, Le Maignan C, Milpied N, Foussard C, Dugay J, Maakaroun A, De Muret A, Colombat P, GOELAMS Group.
    Leuk Lymphoma; 2001 Feb 20; 40(5-6):529-40. PubMed ID: 11426526
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Holle R, Steinhauer UE, Gropp C, Oehl S.
    Ann Oncol; 1994 Jan 20; 5(1):49-55. PubMed ID: 8172793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.